Unknown

Dataset Information

0

Psychophysiological treatment outcomes: Corticotropin-releasing factor type 1 receptor antagonist increases inhibition of fear-potentiated startle in PTSD patients.


ABSTRACT: After exposure to a traumatic event, a subset of people develop post-traumatic stress disorder (PTSD). One of the key deficits in PTSD is regulation of fear, and impaired inhibition of fear-potentiated startle (FPS) has been identified as a potential physiological biomarker specific to PTSD. As part of a larger clinical trial, this study investigated the effects of a CRF receptor 1 antagonist, GSK561679, on inhibition of fear-potentiated startle during a conditional discrimination fear-conditioning paradigm, termed AX+/BX-. Prior research using this paradigm has demonstrated deficits in inhibition of conditioned fear in several PTSD populations. The randomized, double-blind, placebo-controlled clinical trial compared fear inhibition between female PTSD participants taking 350 mg/day GSK561679 (n = 47 pre- and 29 post-treatment) and patients taking a placebo pill (n = 52 pre- and 30 post-treatment) daily for 6 weeks. There was no significant difference between the two groups in their acquisition of fear or discrimination between threat and safety cues, and no pre-post-treatment effect on these measures. However, there was a significant effect of treatment on inhibition of FPS during the AB trials in the AX+/BX- transfer test (p < 0.05). While all PTSD participants showed typical impairments in fear inhibition prior to treatment, GSK561679 enhanced fear inhibition post-treatment, independent of clinical effects. The current study suggests that CRF receptor 1 antagonism may have specific effects within neural circuitry mediating fear inhibition responses, but not overall symptom presentation, in PTSD.

SUBMITTER: Jovanovic T 

PROVIDER: S-EPMC6710166 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Psychophysiological treatment outcomes: Corticotropin-releasing factor type 1 receptor antagonist increases inhibition of fear-potentiated startle in PTSD patients.

Jovanovic Tanja T   Duncan Erica J EJ   Kaye Joanna J   Garza Kristie K   Norrholm Seth D SD   Inslicht Sabra S SS   Neylan Thomas C TC   Mathew Sanjay J SJ   Iosifescu Dan D   Rothbaum Barbara O BO   Mayberg Helen S HS   Dunlop Boadie W BW  

Psychophysiology 20190226 1


After exposure to a traumatic event, a subset of people develop post-traumatic stress disorder (PTSD). One of the key deficits in PTSD is regulation of fear, and impaired inhibition of fear-potentiated startle (FPS) has been identified as a potential physiological biomarker specific to PTSD. As part of a larger clinical trial, this study investigated the effects of a CRF receptor 1 antagonist, GSK561679, on inhibition of fear-potentiated startle during a conditional discrimination fear-condition  ...[more]

Similar Datasets

| S-EPMC3116445 | biostudies-literature
| S-EPMC3080103 | biostudies-literature
| S-EPMC6681462 | biostudies-literature
| S-EPMC3055566 | biostudies-other
| S-EPMC4367474 | biostudies-literature
| S-EPMC3056161 | biostudies-literature
| S-EPMC2864802 | biostudies-literature
| S-EPMC379691 | biostudies-other
| S-EPMC2647968 | biostudies-literature
| S-EPMC3194076 | biostudies-literature